Brokers Set Expectations for Delcath Systems FY2026 Earnings

Key Points

• HC Wainwright raised its FY2026 EPS forecast for Delcath Systems to a profit of $0.13 from a projected loss of $0.17, while maintaining a Buy rating and $36 price target.
• Delcath reported quarterly EPS of $0.17, beating expectations of a $0.09 loss, and revenue of $35.1 million versus the $26.0 million estimate.
• Analyst views are mixed but lean positive: MarketBeat’s consensus is “Moderate Buy,” with an average price target of $29.33; shares recently opened at $21.77.

Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) - Investment analysts at HC Wainwright lifted their FY2026 earnings per share (EPS) estimates for Delcath Systems in a research note issued on Tuesday, November 10th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of $0.13 for the year, up from their prior forecast of ($0.17). HC Wainwright has a "Buy" rating and a $36.00 price target on the stock. The consensus estimate for Delcath Systems' current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for Delcath Systems' Q4 2026 earnings at ($0.10) EPS, Q3 2027 earnings at $0.22 EPS and FY2027 earnings at $0.33 EPS.

A number of other equities analysts have also recently commented on DCTH. Weiss Ratings cut shares of Delcath Systems from a "hold (c)" rating to a "hold (c-)" rating in a research note on Wednesday, October 28th. Zacks Research lowered shares of Delcath Systems from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, October 6th. Wall Street Zen raised shares of Delcath Systems from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th. Finally, BTIG Research raised their price objective on shares of Delcath Systems from $21.00 to $25.00 and gave the stock a "buy" rating in a research note on Monday. Two equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, Delcath Systems has an average rating of "Moderate Buy" and a consensus price target of $29.33.

Delcath Systems Trading Up 8.3%

Shares of DCTH opened at $21.77 on Thursday. The company's fifty day simple moving average is $15.71 and its 200-day simple moving average is $12.59. The company has a market cap of $755.40 million, a P/E ratio of 136.06 and a beta of 0.62. Delcath Systems has a twelve month low of $8.12 and a twelve month high of $22.33.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of ($0.09) by $0.26. Delcath Systems had a net margin of 6.05% and a return on equity of 5.56%. The company had revenue of $35.10 million during the quarter, compared to analyst estimates of $25.99 million.

Institutional Trading of Delcath Systems

Large investors have recently made changes to their positions in the stock. Russell Investments Group Ltd. increased its stake in Delcath Systems by 31.1% in the 3rd quarter. Russell Investments Group Ltd. now owns 88,727 shares of the company's stock worth $1,417,000 after buying an additional 21,069 shares during the period. Alps Advisors Inc. lifted its holdings in Delcath Systems by 30.3% during the 3rd quarter. Alps Advisors Inc. now owns 45,640 shares of the company's stock valued at $729,000 after buying an additional 10,600 shares in the last quarter. Kopp Family Office LLC bought a new stake in Delcath Systems during the 3rd quarter valued at about $450,000. Integrated Wealth Concepts LLC purchased a new stake in Delcath Systems in the 2nd quarter valued at about $48,000. Finally, IFP Advisors Inc purchased a new stake in Delcath Systems in the 2nd quarter valued at about $52,000. 61.12% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Delcath Systems

These are some of the DCTH headlines that stood out recently:

• Positive Sentiment: Delcath reported quarterly EPS of $0.17, compared with analysts’ consensus estimate of a $0.09 loss, and revenue of $35.1 million versus expectations of $26.0 million. The earnings beat has been cited alongside the stock’s recent advance. Article: Delcath Systems Stock Price Up on Better-Than-Expected Earnings
• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast from a loss of $0.17 to a profit of $0.13, and its FY2027 estimate from $0.12 to $0.33. It also improved its Q4 2026 forecast, narrowing the projected loss to $0.10 per share from $0.13. The firm maintains a Buy rating and a $36 price target. Article: Delcath Systems Gets a Buy from H.C. Wainwright
• Negative Sentiment: HC Wainwright slightly lowered its Q2 2027 EPS forecast to $0.11 from $0.12, a modest counterpoint to its broader upward revisions.

Delcath Systems Company Profile

Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver's blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company's HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.